Fernández E, Weissbach U, Sánchez Reillo C, Braña A F, Méndez C, Rohr J, Salas J A
Departamento de Biología Funcional e Instituto Universitario de Biotecnologia de Asturias, Universidad de Oviedo, 33006 Oviedo, Spain.
J Bacteriol. 1998 Sep;180(18):4929-37. doi: 10.1128/JB.180.18.4929-4937.1998.
Mithramycin is an antitumor polyketide drug produced by Streptomyces argillaceus that contains two deoxysugar chains, a disaccharide consisting of two D-olivoses and a trisaccharide consisting of a D-olivose, a D-oliose, and a D-mycarose. From a cosmid clone (cosAR3) which confers resistance to mithramycin in streptomycetes, a 3-kb PstI-XhoI fragment was sequenced, and two divergent genes (mtmGI and mtmGII) were identified. Comparison of the deduced products of both genes with proteins in databases showed similarities with glycosyltransferases and glucuronosyltransferases from different sources, including several glycosyltransferases involved in sugar transfer during antibiotic biosynthesis. Both genes were independently inactivated by gene replacement, and the mutants generated (M3G1 and M3G2) did not produce mithramycin. High-performance liquid chromatography analysis of ethyl acetate extracts of culture supernatants of both mutants showed the presence of several peaks with the characteristic spectra of mithramycin biosynthetic intermediates. Four compounds were isolated from both mutants by preparative high-performance liquid chromatography, and their structures were elucidated by physicochemical methods. The structures of these compounds were identical in both mutants, and the compounds are suggested to be glycosylated intermediates of mithramycin biosynthesis with different numbers of sugar moieties attached to C-12a-O of a tetracyclic mithramycin precursor and to C-2-O of mithramycinone: three tetracyclic intermediates containing one sugar (premithramycin A1), two sugars (premithramycin A2), or three sugars (premithramycin A3) and one tricyclic intermediate containing a trisaccharide chain (premithramycin A4). It is proposed that the glycosyltransferases encoded by mtmGI and mtmGII are responsible for forming and transferring the disaccharide during mithramycin biosynthesis. From the structures of the new metabolites, a new biosynthetic sequence regarding late steps of mithramycin biosynthesis can be suggested, a sequence which includes glycosyl transfer steps prior to the final shaping of the aglycone moiety of mithramycin.
光神霉素是由产色链霉菌产生的一种抗肿瘤聚酮类药物,它含有两条脱氧糖链,一条由两个D-橄榄糖组成的二糖和一条由一个D-橄榄糖、一个D-橄榄糖和一个D-霉糖组成的三糖。从一个赋予链霉菌对光神霉素抗性的黏粒克隆(cosAR3)中,对一个3 kb的PstI - XhoI片段进行了测序,并鉴定出两个不同的基因(mtmGI和mtmGII)。将这两个基因推导的产物与数据库中的蛋白质进行比较,发现它们与来自不同来源的糖基转移酶和葡萄糖醛酸基转移酶相似,包括几种参与抗生素生物合成过程中糖转移的糖基转移酶。通过基因替换使这两个基因独立失活,产生的突变体(M3G1和M3G2)不产生光神霉素。对这两个突变体培养上清液的乙酸乙酯提取物进行高效液相色谱分析,结果显示存在几个具有光神霉素生物合成中间体特征光谱的峰。通过制备型高效液相色谱从这两个突变体中分离出四种化合物,并通过物理化学方法阐明了它们的结构。这两个突变体中这些化合物的结构相同,这些化合物被认为是光神霉素生物合成的糖基化中间体,不同数量的糖部分连接到四环光神霉素前体的C - 12a - O和光神霉素酮的C - 2 - O上:三种含有一个糖的四环中间体(前光神霉素A1)、两个糖的(前光神霉素A2)或三个糖的(前光神霉素A3)以及一种含有三糖链的三环中间体(前光神霉素A4)。有人提出,mtmGI和mtmGII编码的糖基转移酶负责在光神霉素生物合成过程中形成和转移二糖。根据新代谢产物的结构,可以提出一个关于光神霉素生物合成后期步骤的新生物合成序列,该序列包括在光神霉素苷元部分最终形成之前的糖基转移步骤。